Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pande... (ata that further support the potential u...)

HOME >> MEDICINE >> TECHNOLOGY

Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain

Date:8/18/2009

ata that further support the potential use of TCAD therapy for the military, healthcare workers and general public when faced with the global threat of influenza A outbreaks."

The emergence of the novel influenza A/H1N1 strain and declaration of a pandemic has highlighted the potential threat of influenza to public health and the public health system. Because of this strain's "newness" and lack of background immunity in the human population, a far larger number of people may become infected with the virus this flu season. According to the World Health Organization, the 2009 influenza pandemic has spread internationally with unprecedented speed; in past pandemics, influenza viruses have needed more than six months to spread as widely as the novel influenza A/H1N1 virus has spread in less than six weeks.

About TCAD

Adamas is pioneering triple-combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points in the virus proliferation pathway. TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu (oseltamivir phosphate, Roche). Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, act synergistically to provide a much higher level of antiviral activity than single or double drug combination therapies. In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents. Adamas is accelerating development of its TCAD therapy for influenza A by conducting a Phase 2 clinical trial in the Southern Hemisphere where the novel influenza A/H1N1 pandemic is active, and is preparing to initiate a clinical study of TCAD therapy fo
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
2. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
3. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
4. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
6. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
7. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
8. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
9. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
10. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
11. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use

Post Your Comments:

(Date:5/24/2013)... LOS ANGELES , May 24, 2013 An ... gathered on Saturday, May 18, in Santa ... findings on new lung-sparing therapies for MPM, a rare ... and commonly affects the pleura, the lining of the ... Heart, Lung and Blood Institute, the 3rd Annual International ...

(Date:5/24/2013)... May 24, 2013 In accordance with Rule 17.1 ... 14e-1 of the United States Exchange Act, Echo Pharma Acquisition ... for Elan Corporation (NYSE: ELN). Background ... made an offer for the entire of the issued and ... (the "Original Offer"). On 20 May 2013, ...

(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...

Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8 Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 2 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3

[0] International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma [0] Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements [0] 3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement

... 16, 2011 Cancer patients in China ... the announcement that a leading cancer center is acquiring ... VAR). This device is the first high dose rate ... leader in radiotherapy systems. Jilin University ...

... 16, 2011 U L ... announced today that it has filed an abbreviated 510(k) application ... label claim to include the management and mitigation of pain. ... a randomized clinical study comparing Altrazeal® to Acquacel® Ag in ...

Cached Medicine Technology:First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital 2 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3 ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4

First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim

(Date:5/24/2013)... The news about youth and diabetes keeps getting worse. ... that children who develop Type 2 diabetes are at high ... at a higher rate than people who acquire Type 2 ... 2 diabetes, they seem to be at very high risk ... M.D., professor of pediatric endocrinology in the School of Medicine ...

(Date:5/24/2013)... 2013 Fit Yummy Mummy, a fitness ... who are trying to get rid of the belly ... ideal for women who want to combine exercises with ... ’s Stan Stevenson, prompting an investigative review. , “Holly's ... a wide variety of motivational strategies, nutritional plans, proper ...

(Date:5/24/2013)... The Institute for Integrative Nutrition , the ... has donated $10,000 to the Cleveland Courage Fund , ... Ohio. , “When the news came out on Monday, May ... and her daughter had escaped from a Cleveland home after ... horrified,” said Integrative Nutrition Founder, Director, and Primary Teacher Joshua ...

(Date:5/24/2013)... 2013 General Data Company Inc., ... tracking and data management products and solutions, has ... Inc., (TBS) of Durham, North Carolina, a leading ... for the clinical and research pathology marketplace. TBS ... which provides specialty products and solutions to hospitals, ...

(Date:5/24/2013)... Finding the answer for this is at the centre of ... the Bergen fMRI Group at the University of Bergen (UiB) ... The way they do this is by studying people who ... mental illness. For a five-year period, the group is studying ... report published in Frontiers in Human Neuroscience shows ...

Breaking Medicine News(10 mins):Health News:Youth with type 2 diabetes at much higher risk for heart, kidney disease 2 Health News:Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released 2 Health News:Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund 2 Health News:General Data Acquires Triangle Biomedical Sciences 2 Health News:General Data Acquires Triangle Biomedical Sciences 3 Health News:Help at hand for schizophrenics 2

[0] Youth with type 2 diabetes at much higher risk for heart, kidney disease [0] Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released [0] Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund [0] General Data Acquires Triangle Biomedical Sciences [0] Help at hand for schizophrenics

... the 13th time, more than any hospital in the U.S. , ... ... (NorthShore) was named one of the nation,s 100 Top Hospitals® by Thomson ... and quality of healthcare. NorthShore has been named a Top 100 Hospital ...

... (April 1, 2009) It appears that a drug ... similar effect on the compulsive behavior of kleptomaniacs it ... the University of Minnesota., The Medical School,s Department of Psychiatry ... ages 17-75, who spent an average of at least one ...

... KUALA LUMPUR, Malaysia, March 31 Rheumatoid arthritis (RA) ... which the body,s defense system attacks the joints through ... lines and lubricates the joints. The most visible symptoms ... of the hands and feet. It can cause fatigue, ...

... LifeCare Holdings, Inc. (the "Company") today announced its operating ... 2008. Three Months Ended December 31, 2008 ... service revenue of $94.2 million for the three months ended ... the same period in 2007 while patient days were unchanged. ...

... Guideline Reached For Quantitative Polymerase Chain ReactionSALT LAKE CITY, ... and the American Association for Clinical Chemistry ... for a key laboratory method called qPCR (or quantitative ... international scientists representing the medical and research fields. qPCR ...

... The U.S. District Court for the District of ... between Alza Corporation, McNeil-PPC, Inc. and Andrx Pharmaceuticals LLC. ... markets CONCERTA(R) (methylphenidate HCI) Extended-Release Tablets CII, said the ... valid or infringed by the filing of Andrx,s Abbreviated ...

NorthShore University HealthSystem Named One of the Nation's Top 100 Hospitals by Thomson Reuters Drug commonly used for alcoholism, drug addiction, curbs urges of compulsive stealers Frost & Sullivan: Rheumatoid Arthritis Therapeutics in Malaysia LifeCare Holdings, Inc. Announces Year-End Results International Scientists Secure Quality in Molecular Diagnostics District Court Decision Received in CONCERTA(R) Patent Case

... Detection Of Serum C-Peptide ... Measurement:, Evaluating patients ... Assisting in the classification ... Differentiating insulin dependent patients ...

Inquire...

The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....

Inquire...

Medicine Products:

ACS:180 C-Peptide Assay C-Peptide Pach IV Pachymeter RIDASCREEN Anti-Measles Virus IgM Assay